Alzheimer's: Page 3

Alzheimer’s study compares blood-based biomarkers, other detection technologies
The Global Alzheimer’s Platform Foundation technology study, with more than 1,000 participants, focuses on access and diversity.
November 15, 2022
Brain Puzzle Stars Social
NanoMosaic obtains rights to biomarker test for the diagnosis, prognosis of anesthesia-induced delirium, Alzheimer's
The test uses the Tessie system to alleviate bottlenecks in proteomics analysis and to enable protein interrogation as well as multiomics analysis within a single chip during one run.
October 12, 2022
Alzheimers Phases Amyloid
Diadem nabs $2.5M to further validate Alzheimer’s blood test
The two-year grant will enable Diadem, a company that has been developing a blood-based test for the early prediction of Alzheimer's disease (AD), to leverage data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a longitudinal multicenter study designed to enable development of biomarkers for the early detection and tracking of AD.
September 6, 2022
2022 09 07 17 41 6639 Nerve Neuron Axon 400
Roche nabs FDA breakthrough designation for Alzheimer’s Dx
The panel, a blood-based biomarker test, is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
July 18, 2022
2022 07 19 18 45 8071 Alzheimers Phases Amyloid 400
Alzheimer’s test developer Diadem joins DPUK
Diadem's AlzoSure Predict blood test identifies signs of cognitive impairment that will or will not progress to Alzheimer's dementia up to six years before diagnosis.
June 12, 2022
2020 03 31 23 03 5810 Brain Dementia Leaves 400
Diadem highlights new study on AlzoSure test for Alzheimer's
In a retrospective study published online May 17 in the Journal of Prevention of Alzheimer's Disease, researchers reported that AlzoSure Predict achieved an area under the curve (AUC) of more than 0.98 for identifying people who would progress to future symptomatic Alzheimer's disease up to six years before diagnosis.
May 17, 2022
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
New biomarker could detect early Alzheimer’s before symptoms
In addition, the findings have some implications for taking brain-boosting dietary supplements that contain the amino acid serine. The key compound responsible for producing serine in the body is PHGDH. The scientists reported that PHGDH mRNA and protein levels had increased in the brains of two mouse models of Alzheimer's disease or tauopathy.
May 4, 2022
2022 05 05 18 49 5180 Patient Elderly Confused Headache 400
FDA grants approval for Fujirebio assay for Alzheimer's plaques
The FDA granted clearance under its breakthrough device pathway to Fujirebio's Lumipulse G β-Amyloid Ratio (1-42/1-40) test, which is designed to measure the ratio of β-amyloid 1-42 and β-amyloid 1-40. These are proteins that can accumulate and form plaques in the brain; concentrations of these proteins can be detected in cerebral spinal fluid (CSF).
May 3, 2022
2022 05 04 20 54 3251 Computer Brain Hemisphere 400
Quest publishes Alzheimer’s report, unveils blood test
The report, called "The Coming Alzheimer's Disease Healthcare Revolution: U.S. Physician and Adult Perspectives on the Future of Diagnostics and Treatment," found that 66% of physicians believe that "we are on the precipice of groundbreaking new treatment options" for Alzheimer's disease, according to Quest.
May 3, 2022
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
Does race affect interpretation of Alzheimer's disease tests?
An international team led by researchers at Washington University School of Medicine in St. Louis, MO, compared three experimental blood tests and a commercially available Alzheimer's disease test they developed in previous work (PrecivityAD, C2N Diagnostics) in 76 pairs of Black and non-Hispanic white participants.
April 21, 2022
2022 03 01 23 02 5066 Older Woman Anxious 400
Quanterix partners with Alzheimer's research foundation
As part of the partnership, the ADDF will fund a series of prospective clinical trials to validate the test in collaboration with Amsterdam University Medical Centers in the Netherlands. The research will be coordinated through Quanterix's Simoa Accelerator Services Lab, which provides contract research services and clinical sample testing.
March 30, 2022
2019 04 30 23 29 0302 Brain 400
Sysmex, Eisai tout Alzheimer's research at AD/PD 2022
As part of a nonexclusive agreement to create diagnostic agents for dementia, researchers from the companies compared the performance of the plasma beta-amyloid ratio measured using the Sysmex HISCL automated immunoassay system with that of amyloid status on positron emission tomography (PET) imaging as determined by the Centiloid method. Their technique was assessed in a discovery study in 180 patients and in a validation study involving 191 patients who were clinically diagnosed with mild Alzheimer's disease or mild cognitive impairment.
March 22, 2022
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
Previous Page
Page 3 of 6
Next Page